Back to News & Events

Traverse Biosciences Receives Phase 1 STTR Award

Traverse Biosciences announced today that it has received a $223,979 Phase I Small Business Technology Transfer (STTR) award in partnership with the Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. Funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) will be used to evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, for the treatment of osteoarthritis (OA). The research at the Feinstein Institute will be led by Daniel A. Grande, PhD, Director, Orthopaedic Research Laboratory, who will serve as principle investigator on the award in close collaboration with Traverse Biosciences. Read the full press release:

Related Stories

No related post found.